Navigating antibody‒drug conjugates (ADCs): from metastatic to early breast cancer treatment strategies.

Invest New Drugs · 2025 · PMC12310797 · PMID 40304863

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

The addition of pembrolizumab to SG showed a nonsignificant trend toward improved PFS in HR +/HER2− MBC patients at the preliminary time point (2024) and OS data are still immature [ 78 ].

also in 5,406 other papers

showed a trendno p-value reported

The data presented in the ESMO 2024 trial of Morpheus were immature but showed a trend toward benefit with the combination of atezolizumab and SG versus atezolizumab and nabpaclitaxel of 12.2 vs. 5.9 months in patients with mTNBC [ 98 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.